Kura Oncology Inc (KURA)
$17.68
Insights on Kura Oncology Inc
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 282.2%
Performance
- $17.63$18.05$17.68
0.28%
Downside
Day's Volatility :2.33%
Upside
2.05%
- $7.41$24.17$17.68
58.09%
Downside
52 Weeks Volatility :69.34%
Upside
26.85%
Returns
| Period | Kura Oncology Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 23.64% | -0.7% | 0.0% |
6 Months | 114.93% | 6.6% | 0.0% |
1 Year | 63.4% | 3.7% | -1.5% |
3 Years | -34.87% | 14.0% | -21.8% |
Highlights
Market Capitalization | 1.4B |
Book Value | $5.34 |
Earnings Per Share (EPS) | -2.08 |
PEG Ratio | 0.0 |
Wall Street Target Price | 30.25 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -22.9% |
Return On Equity TTM | -37.34% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -165.0M |
Diluted Eps TTM | -2.08 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.32 |
EPS Estimate Next Year | -2.46 |
EPS Estimate Current Quarter | -0.55 |
EPS Estimate Next Quarter | -0.54 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 71.1%
Technicals Summary
Sell
Neutral
Buy
Kura Oncology Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Kura Oncology Inc | -14.5% | 114.93% | 63.4% | -34.87% | 20.66% |
 Moderna, Inc. | -0.79% | 20.27% | -27.48% | -36.11% | 359.53% |
 Regeneron Pharmaceuticals, Inc. | -6.12% | 9.1% | 11.53% | 80.35% | 170.35% |
 Novo Nordisk A/s | -6.29% | 23.82% | 46.7% | 242.59% | 414.69% |
 Vertex Pharmaceuticals Incorporated | -4.44% | 6.95% | 20.9% | 79.35% | 133.77% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Kura Oncology Inc | NA | NA | 0.0 | -2.32 | -0.37 | -0.23 | NA | 5.34 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.71 | 25.71 | 1.46 | 45.13 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.58 | 46.58 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.42 | 28.42 | 0.53 | 16.73 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Kura Oncology Inc | Buy | $1.4B | 20.66% | NA | 0.0% |
Moderna, Inc. | Buy | $39.8B | 359.53% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.1B | 170.35% | 25.71 | 30.14% |
Novo Nordisk A/s | Buy | $551.2B | 414.69% | 46.58 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $101.9B | 133.77% | 28.42 | 36.68% |
Institutional Holdings
BlackRock Inc
9.61%Suvretta Capital Management, LLC
9.12%Bvf Inc
8.84%EcoR1 Capital, LLC
7.63%Deerfield Management Co
5.75%Vanguard Group Inc
5.30%
Corporate Announcements
Kura Oncology Inc Earnings
Kura Oncology Inc’s price-to-earnings ratio stands at None
Read More
Company Information
at kura oncology, we are committed to realizing the promise of precision medicines for cancer. the genomics revolution is transforming how we treat cancer. we now understand that how a patient responds to treatment depends in part on the genetic makeup of the cancer and, importantly, we have the knowledge and tools to create targeted treatments and companion diagnostics to identify those patients most likely to benefit. this new era offers the potential for innovative treatments that are safer and more effective for patients with particular cancers. we are leveraging our insights into cancer genetics as well as our core strength of translating novel science into life-saving medicines to advance a pipeline of precision medicines. our development programs target cancers with high unmet need, including lung, colorectal, thyroid and pancreatic cancers as well as blood cancers such as lymphoma and leukemias. our goal is to help patients with cancer lead better, longer lives.
Organization | Kura Oncology Inc |
Employees | 142 |
CEO | Dr. Troy Edward Wilson J.D., Ph.D. |
Industry | Health Technology |
